480-907-7690 info@qfrsolutions.com
Novan Provides Update on SB204 Development Program

Novan Provides Update on SB204 Development Program

Source: Novan MORRISVILLE, N.C., March 06, 2017 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that, after further analysis of the results from the NI-AC301 and NI-AC302 pivotal clinical trials for the Company’s topical...
Novan Provides Update on SB204 Development Program

Novan Licenses SB204 to Sato for Acne in Japan

Source: Globe Newswire Novan, Inc. (“the Company” or “Novan”) (NOVN) today announced that the Company has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. (“Sato”), a Japanese company with a...